Olokizumab Outperforms Placebo in RA patients on maintenance Methotrexate: NEJM Dr. Kamal Kant Kohli29 Aug 2022 8:00 AM ISTVIENNA: Patients with rheumatoid arthritis taking maintenance methotrexate respond better to olokizumab than to a placebo and non-inferior to...
Sandoz Supplemental Biologics License application accepted by US FDA for biosimilar Hyrimoz high concentration formulation Ruchika Sharma24 July 2022 10:00 AM ISTAdalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a).
Novartis division Sandoz application for proposed biosimilar Hyrimoz's high concentration formulation accepted by EMA Ruchika Sharma19 Jun 2022 11:30 AM ISTUpon approval, the Hyrimoz (100 mg/mL) citrate-free HCF would offer reduced injection volume and potentially decrease the number of injections...
Methotrexate escalation or add on adalimumab- Trial guides selecting initial PsA treatment Medha Baranwal23 March 2022 9:45 AM ISTUK: Results from a phase 4, an open-label study supports the addition of tumor necrosis factor (TNF) inhibitor adalimumab over escalating methotrexate...
Pfizer supplemental application for ABRILADA interchangeability accepted by USFDA for review MD Bureau27 Feb 2022 10:30 AM ISTNew Delhi: Pfizer Inc. has announced that the U.S. Food and Drug Administration (USFDA) has accepted for review the Prior Approval Supplement (PAS) to...
Adalimumab efficacious in conjunction with Surgery in Hidradenitis Suppurativa: Study Dr. Shravani Dali20 Dec 2021 9:00 AM ISTAdalimumab was efficacious in conjunction with Surgery in moderate to severe Hidradenitis Suppurativa, according to a recent study published in the...
Boehringer Ingelheim Cyltezo gets USFDA nod as 1st iterchangeable biosimilar with Humira Ruchika Sharma17 Oct 2021 11:00 AM ISTRidgefield: Boehringer Ingelheim has recently announced that the U.S. Food and Drug Administration (USFDA) has approved the supplemental Biologics...
Use of some biologics increase risk of serious infections in psoriasis patients: JAMA MD Editorial Team14 Oct 2021 9:00 AM ISTFrance: A new study by Laetitia Penso and colleagues reported that the risk of serious infections is increased in new users of infliximab and...
Adalimumab effective in moderate to severe hidradenitis suppurativa: JAMA study Dr. Nandita Mohan27 Sept 2021 9:00 AM ISTAdalimumab was efficacious in patients with hidradenitis suppurativa (HS), with no need to interrupt treatment prior to surgery, suggests a recent...
Intas secures CDSCO panel nod to study arthritis drug Adalimumab Medical Dialogues Team24 Sept 2021 5:08 PM ISTNew Delhi: In a significant development, drug firm Intas has got a green signal from the Subject Expert Committee (SEC) functional under the Central...
Bimekizumab scores over adalimumab in achieving plaque psoriasis clearance: NEJM Medha Baranwal28 April 2021 10:50 AM ISTUK: Bimekizumab was shown to be noninferior and superior to adalimumab in reducing signs and symptoms of plaque psoriasis in a 56-week trial. However,...
Sarilumab scores over adalimumab in improving physical function in RA: Study Dr. Nandita Mohan7 Nov 2020 11:17 AM ISTResearchers have found that sarilumab was associated with better improvements in physical function and morning compared with...
